The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa, BeiGene USA, Inc.) with Obinutuzumab for Relapsed/Refractory Follicular Lymphoma (FL)
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved…
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved…
Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search…
Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred…
Advancing Cures and Developing the Next Generation of Lymphoma Researchers Growing up in Spoleto, Italy,…
On December 1, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
First Lady of Tennessee, Maria Lee, Shares Her Experience with Lymphoma No one ever thinks…
On June 15, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab…
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib…